#USA #South San Francisco #Rigel Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Sees Remarkable Growth in Q4 and Full Year 2025 Financial Results

Rigel Pharmaceuticals, a leading biotechnology firm specializing in hematologic disorders and cancer treatments, has unveiled substantial financial results for the fourth quarter and the entire year of 2025. The company reported total revenues of approximately $69.8 million for the last quarter, which includes a record net product sales figure of $65.4 million. This represents an impressive 41% increase compared to the same period in 2024, when net product sales were $46.5 million.

For the full year 2025, Rigel's total revenues reached about $294.3 million, driven by net product sales of approximately $232.0 million, up 60% from previous year's sales of $144.9 million. The strong financial performance is attributed to the successful market penetration of its key products, including TAVALISSE, GAVRETO, and REZLIDHIA. Notably, TAVALISSE recorded net sales of $158.8 million, a remarkable 52% increase from the previous year.

Record Net Income and Future Prospects

Rigel's financial success also extends to net income, where it reported an eye-catching $268.1 million for the fourth quarter and a total of $367.0 million for the entire year. This is a significant leap compared to last year's figures of $14.3 million for Q4 and $17.5 million for the full year. The net income boost is partly due to a non-cash deferred income tax benefit of $245.9 million received in 2025.

Looking forward, Rigel expects its total revenues for 2026 to be in the range of $275 to $290 million, bolstered by around $255 to $265 million in net product sales. The company also projects a positive net income for the year, demonstrating Rigel's solid financial foundation and strategic planning.

Clinical Advancements and Business Performance

On the clinical front, Rigel is making noteworthy strides in its Phase 1b study involving R289, a novel treatment for patients with lower-risk myelodysplastic syndrome (MDS). The company anticipates completing patient enrollment in the second half of 2026 and selecting the recommended dose for subsequent clinical evaluations.

Rigel’s president and CEO, Raul Rodriguez, expressed pride over the company's performance in 2025, emphasizing strong product sales, increased overall revenues, and advances in clinical studies as key milestones. “These accomplishments not only reflect our core operational strengths but also pave the way for a robust 2026,” remarked Rodriguez.

Key Clinical Developments

In December 2025, Rigel presented updated data from the American Society of Hematology (ASH) Annual Meeting, showing that R289 was well tolerated in patients previously subject to extensive treatments. The study reported a 33% success rate for achieving red blood cell transfusion independence among evaluable patients. Additionally, Rigel showcased promising data surrounding olutasidenib and pralsetinib, which highlighted the efficacy of these therapies in treating various forms of aggressive blood cancers.

The FDA's approval of a supplemental New Drug Application for GAVRETO, signifying advancements in urinary tract indications, gathered significant attention within the medical community, auguring well for Rigel's future endeavors in expanding treatment options for non-small cell lung cancer.

Corporate Governance Changes

In line with its ongoing development, Rigel appointed Michael P. Miller to its Board of Directors as an independent director, which is expected to strengthen its corporate governance.

Rigel’s transparent and sturdy corporate strategies combined with robust clinical advancements set an optimistic tone as it heads into 2026, with expectations of delivering further breakthroughs and growth in the competitive biotech landscape.

With a strong foundation and promising pipeline, Rigel Pharmaceuticals continues to strive towards fulfilling its mission of delivering innovative therapies that enhance the lives of patients facing critical health challenges.